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Preventing the transmission of infectious
diseases through blood transfusion in developing
countries is difficult given that the resources
needed are not always available, even when
policies and strategies are in place (1). Avoiding
paid donors, selecting blood donors through
questionnaires, and limiting the number of
transfusions can prevent the transmission of
infections. Testing for specific antibodies is the
final measure for eliminating unsafe blood.
The risk for transfusion-transmitted infec-
tious diseases can be estimated on the basis of
screening level for each infectious agent and the
prevalence rate of the infection in the donor
population. Estimates may also take into account
the sensitivity, specificity, and window period of
the testing assays. We report here an estimate of
such a risk in 12 Central and South American
countries and the cost of reagents required for the
screening of these infectious diseases as a proxy
of resources needed to reduce the risk.
Source of Information
This report analyzes data from 1993 on
screening of blood donors from five countries
(Costa Rica, El Salvador, Guatemala, Honduras,
and Nicaragua) of Central America. Data were
also analyzed for 1993 from five countries
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We report the potential risk for an infectious disease through tainted transfusion in
10 countries of South and Central America in 1993 and in two countries of South
America in 1994, as well as the cost of reagents as partial estimation of screening
costs. Of the 12 countries included in the study, nine screened all donors for HIV; three
screened all donors for hepatitis B virus (HBV); two screened all donors for
Trypanosoma  cruzi; none screened all donors for hepatitis C virus (HCV); and six
screened some donors for syphilis. Estimates of the risk of acquiring HIV through blood
transfusion were much lower than for acquiring HBV, HCV, or T. cruzi because of
significantly higher screening and lower prevalence rates for HIV. An index of infectious
disease spread through blood transfusion was calculated for each country. The highest
value was obtained for Bolivia (233 infections per 10,000 transfusions); in five other
countries, it was 68 to 103 infections per 10,000. The risks were lower in Honduras
(nine per 10,000), Ecuador (16 per 10,000), and Paraguay (19 per 10,000). While the
real number of potentially infected units or infected persons is probably lower than our
estimates because of false positives and already infected recipients, the data
reinforce the need for an information system to assess the level of screening for
infectious diseases in the blood supply. Since this information was collected, Chile,
Colombia, Costa Rica, and Venezuela have made HCV screening mandatory;
serologic testing for HCV has increased in those countries, as well as in El Salvador
and Honduras. T. cruzi screening is now mandatory in Colombia, and the
percentage of screened donors increased not only in Colombia, but also in Ecuador,
El Salvador, and Paraguay. Laws to regulate blood transfusion practices have been
enacted in Bolivia, Guatemala, and Peru. However, donor screening still needs to
improve for one or more diseases in most countries.6 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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(Bolivia, Chile, Colombia, Peru, and Venezu-
ela) and for 1994 from two countries (Ecuador
and Paraguay) of South America. Information
was obtained from Ministry of Health reports
during technical meetings in which the
situation of each country was reviewed (2-5) or
from an official report (6).
In addition, data are presented on the least
expensive reagents for detecting antibodies for
HIV, hepatitis C virus (HCV), Trypanosoma
cruzi, and Treponema pallidum, and for detecting
hepatitis B virus (HBV) antigen (HBsAg) (2,3).
All data are national except for Peru, where the
information was for the city of Lima only (3).
Population data were from the Pan American
Health Organization’s publication Health Condi-
tions in the Americas (7). Estimates are based on
reported results of donor screening activities (2-6).
Assumptions
For the best possible scenario, the following
assumptions were made: 1) Because the
laboratory procedures and brands of reagents
used in the 12 countries may differ in sensitivity
and specificity, comparisons between them are
not straightforward. In addition, results of the
screening are influenced by the existence of an
organized system of quality control and profi-
ciency testing for the serology and for the
evaluation of the diagnostic kits, which most
countries lacked from 1993 to 1994. Most
countries reported the use of different brands of
second, third, and fourth generation immuno-
logic assays for screenings of HCV, HIV, and
HBV, respectively. Therefore, we assumed that
the specificity of the tests for viral diagnosis was
100%, but the sensitivity was 90.00% for HCV,
99.99% for HIV, and 99.90% for HBV. These
specificity and sensitivity estimates fit well with
those reported for second, third, and fourth
generations of assays for HCV, HIV, and  HBV,
respectively, as mentioned in the package insert
by two of the manufacturers of reagents used in
the countries. Average window periods for those
assays were 20 to 25 days (8,9), 82 to 84 days
(9,10), and 51 days (9) for HIV, HBV, and HCV,
respectively. In the case of T. cruzi serology, we
selected the upper range of reported sensitivity
and specificity (90% and 95%, respectively)
(11,12). For T. cruzi, the probability that a person
may become a donor during the window period is
low because infection is usually acquired in
childhood and in rural areas. 2) We assumed that
prevalence of infection in unscreened donors was
the same as the national average prevalence for
each infectious disease. 3) Chile (6) and Peru (3)
were the only countries that reported a fraction-
ation index, 1.85 and 1.5, respectively. As no other
country provided data on the fractionation index or
data allowing one to be calculated, to put the
countries in the same category, it was assumed that
every blood donation corresponded to a single
transfusion to one recipient.
Screening Coverage and Prevalence Rates
Table 1 shows coverage of screening and
prevalence rates of seropositive tests for specific
infectious agents among blood donors reported by
each of the 12 countries. For HIV, 100% of the
donors were screened in all countries, except
Bolivia (36.20%), Ecuador (89.50%), and Colom-
bia (98.80%). Prevalence rates for HIV varied
from 3.90 per 1,000 in Honduras to 0.04 per 1,000
in Nicaragua. For HBV, only Costa Rica, Peru,
and Venezuela screened 100% of donors. The
highest values of HBV prevalence estimated were
14.40 per 1,000 for Venezuela and 13.00 per 1,000
for Paraguay. Bolivia, Costa Rica, and Paraguay
did not screen for HCV at all, and all other
countries screened fewer than 58% of donors;
prevalence rates varied from 0.50 to 9.40 per
1,000. Screening for syphilis was not complete in
Bolivia, Chile, Colombia, Ecuador, Nicaragua,
and Paraguay; prevalence rates were 5.00 to
28.00 per 1,000. For T. cruzi infection, only
Venezuela and Honduras screened 100% of
donors; prevalence rates were 2.00 per 1,000 in
Ecuador to 147.90 per 1,000 in Bolivia. In 1993,
Peru and Costa Rica had not yet introduced
screening for T. cruzi.
Estimating Potential Infectivity of the
Blood Supply
The probability of receiving an infected
transfusion unit P(R) in each country was
estimated by multiplying the prevalence of a
specific infection by 1-level of screening (Table 1).
For those estimates, the sensitivity and
specificity of the different tests were taken into
account. As the overall assumed sensitivity of
HIV screening was 99.99%, the adjustment of
prevalence rates makes no material difference to
the precision of the figures in Table 1. The
probability of getting a transfusion-transmitted
infection P(I) was calculated as the result of the
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P(R) multiplied by the infectivity risk. For
countries reporting 100% of screening coverage
for a specific disease, a residual P(R) was
estimated as prevalence x 1-screening sensitivity
(Table 2). Infectivity risk (defined as the likelihood
of being infected when receiving an infected
transfusion unit) was assumed to be 90% for HIV
(13), 75% for HBV (14), 90% for
HCV (15), and 20% for T. cruzi
(16) (Table 2). Estimates for
transfusion-acquired syphilis
are not presented because the
infectivity risk depends on
length of refrigeration (17).
Considering the low preva-
lence rates and the incomplete-
ness of HIV screening, only
Bolivia, Colombia, and Ecua-
dor could have missed detect-
ing an HIV-infected transfu-
sion unit; the probability of
getting an infection in these
countries was estimated at
0.57, 0.22, and 0.95 per 10,000
transfusions, respectively. For
HBV and HCV this risk is
higher. Up to 14.21 HBV
infections (Nicaragua) and 67.09
HCV infections (Colombia)  per
10,000 transfusions may have
occurred. The highest risk for
transfusion-transmitted infection was estimated
for T. cruzi: 219.28 per 10,000 and 49.56 per
10,000 for Bolivia and Peru, respectively, and
approximately 2 to 24 per 10,000 for the other
seven countries (Table 2).
Table 3 shows estimates of the absolute
number of infections that may have been induced
Table 1. Coverage of screeninga of blood donors and seroprevalence rates (per 1,000) of infectious diseases, by
countryb
HIV HBVc HCV Syphilis T. cruzi
Country Cov.d Prev.e Cov. Prev. Cov. Prev. Cov. Prev. Cov. Prev.
(%) (/103) (%) (/103) (%) (/103) (%) (/103) (%) (/103)
Bolivia   36.2  0.10   14.5   2.00   0   ?f   37.9  18.10   29.4 147.90
Chile 100  3.40   98.7   2.00 34.0 6.40   95.2  11.40   76.7   12.00
Colombia   98.8  2.00   98.3   7.00 24.7 9.00   87.3  13.00     1.4   12.00
Costa Rica 100  0.34 100   4.50   0   ? 100    5.00     0     ?
Ecuador  89.5  1.00   88.2   3.80 32.9 1.40    86.7  11.50   51.0     2.00
El Salvador 100  1.30   96.0   8.00 31.4 2.50 100  19.00   42.5   14.70
Guatemala 100  3.00   79.8   7.00 37.2 8.00 100  19.00   75.0   14.00
Honduras 100  3.90   83.5   2.70 27.8 0.50 100    7.00 100   12.40
Nicaragua 100  0.04   53.1   4.00 53.1 4.40   88.4  16.00   58.4     2.40
Paraguay 100  0.70   92.9 13.00   0   ?   66.9  28.00   86.8   45.00
Peru 100  2.80 100   8.60 57.4 4.40 100    9.60     0   23.60g
Venezuela 100  2.10 100 14.40 31.0 9.40 100  10.70 100   13.20
a
Coverage  of screening = (number of screened donors ÷ total number of donors) x 100.
b








Screening not performed and prevalence not known.
g
Data from a survey of 2,237 samples.
Table 2. Probability of receiving an infected transfusion P(R)a and probability
of getting a transfusion-transmitted infection P(I)b, by countryc
HIV HBV HCV T. cruzi
(x104) (x104) (x104) (x104)
Country P(R) P(I) P(R) P(I) P(R) P(I) P(R) P(I)
Bolivia 0.64 0.57 17.27 12.95  NSPd  NSP 1096.38 219.28
Chile 0.00 0.00   0.26   0.20 46.46 41.82     29.36     5.87
Colombia 0.24 0.22   1.20   0.90 74.55 67.09   124.24   24.85
Costa Rica 0.00 0.00   0.45x   0.34  NSP  NSP     NSP     NSP
Ecuador 1.05 0.95   4.52   3.39 10.33   9.38     10.29     2.06
El Salvador0.00 0.00   3.23   2.42 18.87 16.97     88.75   17.75
Guatemala 0.00 0.00 14.28 10.71 55.26 49.74     36.75     7.35
Honduras 0.00 0.00   4.49   3.37   3.97   3.57     13.02x     2.60
Nicaragua 0.00 0.00 18.95 14.21 22.70 20.43     10.48     2.10
Paraguay 0.00 0.00   9.32   6.99 NSP NSP     62.37   12.47
Peru 0.00 0.00   0.87x   0.65 20.62 18.56   247.80   49.56
Venezuela 0.00 0.00   1.45x   1.09 71.35 64.21     13.86x     2.77
aP(R) = probability of receiving an infected transfusion = prevalence of infection x
1- level of screening; xfor countries in which reported screening level was 100%, a
residual P(R) was estimated as prevalence x 1- screening sensitivity rate x 10,000.
bP(I)  = probability of getting a transfusion-transmitted infection = P(R) x
infectivity index (infectivity indexes used were HIV=90%; HBV=75%; HCV=90%;
T.cruzi=20%).  For calculations of P(R) and P(I) the prevalence was corrected
taking into account the sensitivity of the screening.
cData from 1993, except for Ecuador and Paraguay, which were for 1994.
dNo Screening  performed, so P(R) and P(I) not known.8 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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by transfusion, calculated as [no. of donors x P(I)],
for each country. Because Chile (6) and Peru (3)
reported fractionation of blood units by 1.85 and 1.5,
respectively, the estimated number of infected
units transfused in those countries was multiplied
by these factors. For the remaining countries, it was
assumed that each donated unit was given to only
one recipient. An index of infectious disease spread
through blood transfusion was calculated by
dividing the estimated total number of transfusion-
related infections (for any one of the infectious
agents considered) by the total number of donors.
This index indicates the health risks associated
with blood transfusion and can be used as an
outcome indicator to assess the cost-effectiveness of
screening programs.
The highest value for the infection spreading
index was obtained for Bolivia, where 233
transfusion-related infections may have occurred
per 10,000 donations. This was a result of a very
high prevalence rate of antibodies to T. cruzi and
a lower level of screening. For most other
countries considered, the index was 68 to 103
infections per 10,000 donations. Due to low
seroprevalence rates and good screening levels in
some cases, the risk for transfusion-related
infections was relatively low in Honduras (nine
per 10,000), Ecuador (16 per 10,000), and
Paraguay (19 per 10,000).
Table 3 also shows the ratio of number of
infections per donation by country. One infection
(HIV, HBV, HCV, or T. cruzi) might have been
transmitted in every 43 (Bolivia) to 1,072
(Honduras) donated units.
Screening Costs
The unitary cost for serologic screening,
estimated solely from expenditures on the least
expensive laboratory reagents in each country
and considering the prevalence rates reported by
the countries was US$0.9 to US$2.4 for an HIV
enzyme-linked immunosorbent assay (ELISA),
US$0.5 to US$3.5 for HBV screening (enzyme
immunoassay, radioimmunoassay, or passive
reverse hemagglutination), US$3.5 to US$10.0
for HCV ELISA, US$0.25 to US$1.0 for a T. cruzi
test (ELISA, radioimmunoassay, or indirect
hemagglutination) (Table 4), and US$0.09 to
US$0.60 for syphilis serology (RPR or VDRL).
Using other tests might have increased the costs
significantly for some of the infections. For
example, the rapid agglutination test for HIV is
usually more expensive than ELISA.
The cost of preventing the transfusion of one
infected unit was estimated as [(no. of donors x
cost of each test)/ total number of positive donors]
as reported by each country. This value
represents the cost of detecting one unit positive
for any one of the infections
studied in each country by
using one diagnostic test for
each infectious disease. For
example, using two tests, one
for antibody detection and one
for antigen detection of HIV,
increases costs. Detection of T.
cruzi was the least expensive
(US$11-$209 per positive unit),
followed by HBV (US$90-
USS$599 per unit), HCV
(US$438-$7,136 per unit), and
HIV (US$232-$23,000 per unit)
(Table 4). The wide variation of
cost primarily reflects differ-
ences in the prevalence of each
infection and in the cost of each
test in the countries.
The costs per capita to
carry out a complete screening
of blood donors in each country
was US$0.008 to US$0.04 for
HIV, US$0.008 to US$0.02 for
Table 3. Estimates of transfusion-transmitted infectious diseases, by countrya
Infection
Absolute no. of transfusion- spreading Ratio of
No. of transmitted infectious diseasesb indexc infections:
Country donors HIV HBV HCV T. cruzi Total /104 donations
Bolivia   37,948 2 49  NAe 832   883 233 1:43
Chiled 217,312 0   8 1681 236 1925   88 1:113
Colombia 352,316 8 32 2364 875 3279   93 1:107
Costa Rica   50,692 0   2f  NA NA  NA   NA   NA
Ecuador   98,473 9 33     92   20   154   16 1:639
El Salvador   48,048 0 12     82   85   179   37 1:268
Guatemala   45,426 0 49   226   33   308   68 1:147
Honduras    27,885 0   9     10     7f     26     9 1:1072
Nicaragua    46,001 0 65     94   10   169   37 1:272
Paraguay    32,893 0 23  NA   41     64   19 1:514
Perug    52,909 0   4f   147 393   544 103 1:97
Venezuela  204,316 0 22f 1312   57f 1391   68 1:147
aData from 1993 except for Ecuador and Paraguay, which were for 1994.
bNumber of cases transmitted by blood transfusion = [number of donors x P(I) ]. For
calculations of number of infections, the prevalence was corrected taking into account
the sensitivity of the screening.
cInfection spreading index = (total number of infections transmitted ¸ number of donors)
x 10,000.
dFractionation index = 1.85.
eData not available.
fResidual infectivity considering that sensitivity of diagnostic tests is not 100%.
gFractionation index = 1.5.9 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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HBV, US$0.01 to US$0.08 for HCV, US$0.0008 to
US$0.003 for syphilis, and US$0.0025 to
US$0.009 for T. cruzi.
Condition of the Blood Supply
These estimates indicate that the condition of
the blood supply in Central and South America is
far from ideal. Roughly, one case of transfusion-
related infection occurs every 43 to 1,072
donations, varying with the infectious agent and
the country.
In three of the 12 countries, transfusion
recipients might become infected with HIV; in
nine countries, with HCV; in all countries, with
HBV; and in ten countries, with T. cruzi.
However, it was not possible to establish the
potential number of tainted units/infections from
countries in which there was no information on
donor prevalence for HCV (e.g., Bolivia, Costa
Rica, and Paraguay).
No serologic tests for T. cruzi were done in
Costa Rica and Peru. Data on the prevalence of T.
cruzi serology in blood donors from Costa Rica
from 1983 to 1985 (18,19) suggest a risk. Data
from a recent report of a survey among donors in
Lima indicate a prevalence of 2.36% (3). If this is
the real prevalence in the city, the number of
tainted units transfused would have been 1,872
in 1993, while the number of persons infected
through blood transfusion could have been 393.
On the other hand, considering the number of
donors and the prevalence of the infection in the
12 countries, if blood had not been screened at all,
more than 35,000 infected units would have been
transfused. However, infections have different
patterns of evolution. HIV-infected persons are
expected to get AIDS at some time during their
lives (20), while only 50% and 38% of persons,
respectively, will get posttransfusion hepatitis
after infection with HBV or HCV (21). On the
other hand, 20% to 30% of those infected with
T. cruzi will get Chagas disease (16,18,19).
Limitations of the Data
Difficulties and limitations of the use of
public health data for policy decisions, even in
industralized countries, are well recognized.
Figures presented here were generated to
establish an approximation of the problem by
providing an overview of the risk of receiving
Table 4. Estimated unitary cost of preventing transfusion-transmitted infections, by country, 1993a
Cost (US$)
HIV HBVb HCV T. cruzi
Preventing Preventing Preventing Preventing
Single one infected Single one infected Single one infected Single one infected
Country test unit test unit test unit test unit
Chile 2.3      676 1.2c 599    3.5d    547  NAe NA
Costa Rica 1.1   3,280 0.5c 111   NA   NA  NA  NA
Ecuadorf 1.7   1,708 1.0c 263  10.0 7,136 0.35g 175
El Salvador 2.0   1,550 1.9c 238    4.5 1,802 1.0g,h   68
1.0
Guatemala 1.8      601 1.7c 243    3.5    438 0.9g   65
Honduras 0.9      232 0.9c 334    3.5 6,971 0.45h   36
0.5h 186
Nicaragua 1.0 23,000 0.5h 125    3.5    797 0.5h 209
Peru (Lima) 2.4      858 3.5c 407    8.2 1,862 0.25g   11
2.4i 279
Venezuela 1.3      619 1.3c   90    4.5    479 0.5   38
0.3g   23
aCost of preventing (=detecting) one infected unit was calculated as [(number of donors x test cost) ÷ (total number of positive
donors detected)]. All costs refer to enzyme-linked immunosorbent assay, unless otherwise indicated.
bHBsAg only
cEnzyme immunoassay.
dEstimated cost based on cost of test in other countries.
eData not available.
fDonors and prevalence for 1994, costs for 1993.
gIndirect hemagglutination.
hRadioimmunoassay.
iPassive reverse hemagglutination.10 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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tainted blood in different countries in Central
and South America. One potential cause of
underestimation of viral infections transmitted
by blood is the residual risk because of the
window period, even when 100% of donors are
screened by serology (8,9). However, this residual
risk would be difficult to ascertain in most
countries of Central and South America.
Investigation of clinically identified cases after a
transfusion, follow-up of recipients for
seroconversion, and special laboratory studies
detecting seronegative donors for missed infec-
tions are laborious and expensive and could
seldom be undertaken in those countries.
Another possibility would be studies that
combine estimates of incidence rates of infection
among repeated and first-time donors (who
seroconvert) with estimates for the duration of
the preseroconversion period for a specific
infectious agent (22). Excellent results were
obtained by this method in the United States,
where more than 80% of donations come from
repeat donors. Those studies involved hundreds
of thousands of donors and millions of donations.
To have incidence data on repeat donors, it is
necessary to have a significant number of
voluntary donors who will repeat donations.
Therefore, it is unlikely that studies of that sort
could be carried out in the countries mentioned
here. First, the population of the countries is
much smaller; therefore, the number of donations
is smaller. For example, in all Central America
the number of donations is approximately
210,000 per year. Second, the number of repeat
donations from voluntary donors is small.
Voluntary donors accounted for 30% and 40% of
all donations in Colombia and Costa Rica and 4%
to 10% of all donors in Chile, Bolivia, Peru, and
Venezuela (2-6). The number of voluntary donors
was also small in the remaining countries. In all
countries of Central and South America, most
donations come from directed donors, relatives or
friends of patients. In addition, there is no
national registry of donors to allow for follow-up.
Using incidence rates for first-time donors
instead of repeat donors is not a solution because
official incidence rates for HIV or other viruses
were not available at the time of this study.
The risk for transfusion-related infection
could also be overestimated. Recipients may
already be infected. This is especially likely for T.
cruzi infection in Bolivia, where the
seroprevalence in the general population could be
higher than 20% (18,19). Another source of
overestimation is that only some of the cases
detected by screening would be confirmed. In
several countries, a confirmatory test is
mandatory for HIV, syphilis, and HCV. However,
as the primary function of blood banks is donor
screening, seropositive donors for any of the
diseases mentioned here are usually referred to
specialized services or reference laboratories for
confirmation of the results of the screening, and if
results are confirmed, for treatment and
counseling. Results of this confirmatory serology
are not often sent back to the blood bank, even
when privacy concerns allow for it. Chile was the
only country that reported results of confirma-
tory tests for HIV: results indicated that only 9%
of those found positive by the screening were
confirmed positive (6). With T. cruzi, as there is
no confirmatory test, it is assumed that a true
positive is a unit that is positive on more than one
test. By these criteria, a recent study in Brazil
suggested that only one out of five donors positive
for  T. cruzi could be considered a true positive
(23). Those facts, however, do not reduce the
public health relevance of the problem presented
here, although the real numbers of potentially
infected units/infected persons may be still lower
than our estimates.
Establishment of a screening process in every
country will depend on balancing the benefits and
costs. Although costs for preventing transfusion
of one tainted unit or preventing one infection
seem high for some etiologic agents, they are not
so. Even in the case of Nicaragua, the country
with the lowest HIV prevalence, the cost to
prevent the transfusion of one potentially HIV-
infected unit (by testing all donors with ELISA)
was estimated at US$23,000, while treatment
costs (drugs only) for an AIDS patient would be
approximately US$12,000 per year.
In general, the risk for an infectious disease
through tainted transfusion is not as high as that
reported from some countries of Africa (24). Since
1993, donor screening has improved in several
countries. Chile, Colombia, Costa Rica, and
Venezuela, for example, have made screening for
HCV mandatory, and coverage for serology for
that infection has increased in those countries, as
well as in El Salvador and Honduras. T. cruzi
screening is now mandatory in Colombia, and the
percentage of screened donors not only increased
in Colombia but also in Ecuador, El Salvador, and
Paraguay. Laws to regulate blood transfusion11 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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practices have been enacted in Bolivia, Guatemala,
and Peru. The figures presented, however,
underline the need for improvement and stress the
importance of an information system that allows
assessing the level of screening for infectious
diseases in the blood supply. Universal screening of
donors for HCV is still a priority in most countries,
and increased donor screening for T. cruzi is a
priority for Bolivia and possibly for Peru.
Continuous collection of the type of informa-
tion shown here, which has only been partially
available (1), provides a baseline against which
future achievements can be measured and is
essential for obtaining the support needed to
maintain or expand the screening of blood donors.
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